Norovirus Gastroenteritis in Immunocompromised Patients
To the Editor: Bok and Green (Nov. 29 issue) 1 expertly summarize the epidemiologic features, diagnosis, prevention, and management of norovirus infection in immunocompromised hosts. We emphasize the authors' point about handwashing as the mainstay of prevention. A very low infectious dose is required to transmit disease. 2 Because data on the efficacy of alcohol-based hand sanitizers against norovirus are inconclusive, the Centers for Disease Control and Prevention recommends washing with soap and running water. The isolation of infectious patients and environmental decontamination with sodium hypochlorite-based cleaning solutions are other important strategies. 4 We present a case of new-onset collapsing focal segmental glomerulosclerosis and antibodymediated rejection that occurred 1 month after kidney transplantation in association with AT1-receptor antibodies. A 36-year-old white man with end-stage renal disease resulting from lupus nephritis type IV was referred for a third kidney transplantation, although he was already broadly presensitized. He received a kidney from a living, HLA-incompatible, ABO-incompatible donor who was not a relative under the auspices of a kidney-paired donation. The patient underwent a desensitization protocol, given an initial positive flow cytometric cross-match and an anti-B antibody titer of 1:32. The transplanted kidney functioned immediately, and the patient was discharged with a creatinine level of 0.9 mg per deciliter (79.6 μmol per liter).
A biopsy specimen obtained in accordance with a 1-month protocol revealed antibody-mediated rejection and focal collapsing glomerulopathy (Fig. 1A) . Electron microscopy showed complete podocyte effacement (see Fig. S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Donor-specific antibodies (B37, DP1, DP11) were present at very low levels. The anti-B titer was 1:1 (detected only in an undiluted sample) and an antiendothelial cross-match was negative. New proteinuria of 2+ on a screening dipstick test was noted, but the patient's blood pressure and creatinine level were normal. AT1-receptor antibodies were detected in serum that was obtained 2 weeks before and 2 days after the biopsy. The patient received a diagnosis of antibody-mediated rejection 5 and focal segmental glomerulosclerosis associated with alloimmune injury and AT1-receptor antibody. Plasmapheresis, intravenous immunoglob-ulin therapy, and losartan therapy were initiated. After the fifth plasmapheresis treatment (Fig. 1B) , AT1-receptor antibodies could not be detected. A specimen obtained during a follow-up biopsy performed 2 days after the completion of plasmapheresis showed resolving lesions. At 6 months after transplantation, the patient's creatinine level was 1.3 mg per deciliter (114.9 μmol per liter) and the urinary protein-to-creatinine ratio was 0.07. A biopsy specimen showed no antibody-mediated rejection or focal segmental glomerulosclerosis.
This case suggests that the AT1-receptor-mediated pathway may contribute not only to antibody-mediated rejection but also to de novo collapsing focal segmental glomerulosclerosis with severe podocyte effacement. In this patient, depletion of AT1-receptor antibody with plasmapheresis and losartan therapy were associated with the resolution of antibody-mediated rejection and collapsing focal segmental glomerulosclerosis and a marked decrease in podocyte injury. We speculate that the AT1-receptor antibody may explain some cases of antibody-mediated rejection in patients without anti-HLA, ABO, and endothelial antibodies and that it may play a role in podocyte injury in association with focal segmental glomerulosclerosis. Nada Alachkar, M.D. 
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